François Doz

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020 · 955 citations · Full text

Phase 1/2, Surgical Oncology, Tumoral Pathology +9

Subgroup-specific structural variation across 1,000 medulloblastoma genomes

Paul A. Northcott, David Shih, John Peacock et al. · Nature · 2012 · 910 citations · Full text

Genetics, Genomics, Cancer Biology +23

Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition

Marcel Kool, David Jones, Natalie Jäger et al. · Cancer Cell · 2014 · 764 citations · Full text

Tumor Heterogeneity, Medicine, Genetics +8

Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial

Birgitta Lannering, Stefan Rutkowski, François Doz et al. · Journal of Clinical Oncology · 2012 · 321 citations · Full text

Cytogenetic Prognostication Within Medulloblastoma Subgroups

David Shih, Paul A. Northcott, Marc Remke et al. · Journal of Clinical Oncology · 2014 · 307 citations · Full text